Study on MMR Vaccine Injection for Pancreatic Cancer That Can't Be Removed by Surgery

Sponsor: University of Arkansas

Sponsor score: 40

ClinicalTrials ID:NCT07539155

Provider View

This clinical trial is exploring whether injecting the MMR vaccine directly into pancreatic tumors is safe and can help shrink tumors in patients whose cancer cannot be surgically removed after standard treatments.

Patient Parameters

Program Overview

The study aims to find out if injecting the measles, mumps, and rubella (MMR) vaccine directly into pancreatic tumors is safe and effective in reducing tumor size. This trial is for patients with locally advanced pancreatic cancer that cannot be removed by surgery, even after receiving standard chemotherapy and radiation therapy.

Description

This study involves patients with pancreatic cancer that is locally advanced and cannot be surgically removed, even after standard treatments like chemotherapy and radiation. The trial will test the safety and effectiveness of injecting the MMR vaccine directly into the tumor using a procedure called endoscopy. Patients who have already received standard chemotherapy (such as FOLFIRINOX or Gemcitabine with Abraxane) and radiation but still have tumors that cannot be removed by surgery are eligible to participate. The goal is to see if this vaccine injection can help shrink the tumors.

Eligibility Criteria

Inclusion Criteria

  • Must be 18 years or older.
  • Have a confirmed diagnosis of locally advanced pancreatic cancer.
  • Cancer must be considered borderline resectable or unresectable after standard chemotherapy and radiation, based on specific medical criteria.
  • Have previously received chemotherapy and radiation therapy.
  • Have a good overall health status, with an ECOG performance score of 0 or 1.
  • Have adequate blood cell counts and organ function, including liver and kidney function, as determined by specific blood tests.

Exclusion Criteria

  • Cancer that was or has become removable by surgery after standard treatment.
  • Have cancer that has spread to other parts of the body.
  • Be pregnant, breastfeeding, or planning to become pregnant.
  • Have received any live vaccines, including MMR, within 30 days before starting the study.
  • Have received any other cancer treatments within a specified time before starting the study.
  • Have unresolved side effects from previous cancer treatments.
  • Have any other condition that might interfere with the study, as determined by the study doctor.

Locations

FACILITYZIPCITYSTATE
University of Arkansas for Medical Sciences72205Little RockArkansas

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.